Adam H Schechter

CEO Adam H Schechter sold 5,903 shares of LH at $254.50 on 2026-05-11 under pre-arranged 10b5-1 plan; holds 107,234 shares post-sale.

Adam H Schechter, President & CEO, executed a scheduled sale of 5,903 shares at $254.50 on 2026-05-11 under a pre-arranged 10b5-1 trading plan, reducing his holdings from 113,137 shares to 107,234 shares. This is the sixth consecutive sale at LH, with prior same-ticker trades showing mixed short-term outcomes: 30-day returns ranging from -7.2% to +4.5%, and 90-day returns from -9.5% to +6.9%. The current stock price of $266.16 is -9.4% from the 52-week high, though up +4.6% over the past 30 days. Because this transaction is scheduled under a 10b5-1 plan rather than discretionary, it reflects a pre-committed execution strategy rather than a market timing decision. The pattern of regular sales warrants tracking against quarterly fundamentals and broader market movement to assess whether systematic reductions signal changing conviction or represent a predetermined portfolio adjustment plan.

Schechter (CEO) sells 8,705 LH shares at $279.96; holds 80,773 post-transaction

Adam H. Schechter, President & CEO, sold 8,705 shares of LabCorp at $279.96 on 2026-03-03 for a total value of $2,437,047.45. Post-transaction, he retains 80,773 shares, representing a -9.7% reduction in his disclosed holdings. Schechter's historical performance selling at LabCorp is mixed: across his 5 prior trades at LH, only 1 of 4 measurable sales showed a 90-day positive outcome (well-timed by the standard that negative post-sale returns indicate foresight of decline). The transaction occurs when LH stock is at $275.92, down -5.2% from the 52-week high of $290.93, while the company's fundamentals remain solid (quarterly revenue of $3,563,500,000.00, net income of $261,100,000.00, and annual revenue growth of +7.2%), yielding a P/E of 23.07. This sale is routine portfolio activity and does not suggest a material shift in CEO conviction.

CEO Adam Schechter sold 5,273 shares of LH at $284.38 on 2026-02-11 for $1,499,535.74 (1.5M)

Adam H. Schechter, President & CEO, sold 5,273 shares at $284.38, reducing holdings by 5.6% from 94,751 to 89,478 shares. This is his 6th open-market sale across all tickers; however, his prior trades at LabCorp show mixed timing—only 1 of 5 prior LH sales occurred before subsequent 90-day gains, suggesting inconsistent entry/exit discipline specific to this issuer. The stock currently trades at $282.63, down 2.8% from its 52-week high of $290.93, while the broader 30-day trend is positive at +7.9%, indicating the sale occurred near cyclical strength rather than weakness. LabCorp's fundamentals remain solid with $3.6B quarterly revenue, +7.0% annual growth, and a 27.39 P/E, leaving no obvious valuation distress as a catalyst for the transaction.

CEO Schechter sells 5,745 LH shares at $262.75; holds 87,574 post-sale (-6.2% reduction)

Schechter Adam H, President & CEO of LabCorp, sold 5,745 shares on 2025-11-11 for $262.75 per share, reducing his holdings by 6.2% to 87,574 shares. The transaction occurred near the 52-week trading range but 7.9% below the high. At this same ticker, his prior four sales generated mixed 90-day outcomes: one well-timed (negative return), three poorly timed (positive returns), suggesting a 25% hit rate on timing at LH specifically. The company's fundamentals remain solid with $3.6B in quarterly revenue, +7.0% annual growth, and a P/E of 25.96, providing no obvious distress signal. The sale appears routine in size and does not materially signal material concern about the business.

CEO Schechter sells 5,643 LH shares at $266.78; holdings down to 93,319 shares post-sale

Schechter Adam H (President & CEO) sold 5,643 shares of LABCORP HOLDINGS INC. (LH) at $266.78 on 2025-08-11, reducing his holdings by 5.7% to 93,319 shares. The sale occurred near the 52-week high of $272.54, with LH trading at +9.1% over 30 days and +10.7% over 90 days at time of filing. Schechter's three prior sales at LH all generated positive 90-day returns (ranging +1.2% to +6.9%), meaning none were well-timed by the insider's own historical pattern; this sale's timing relative to subsequent price action remains to be observed. The company shows solid fundamentals with $3.5B quarterly revenue, +7.0% annual growth, and a P/E of 29.66, though the stock's recent momentum and proximity to 52-week highs provides context for the CEO's liquidation decision.

LH CEO Adam Schechter sold 6,105 shares at $248.73 (May 12); retains 98,962 shares. Stock up 12.9% in 30 days.

Schechter sold 6,105 shares for $1,518,496.65, reducing his position by 5.8% but maintaining substantial holdings of 98,962 shares. His prior two sales at LH produced negative 90-day returns of -3.7% and -5.7%, yet both trades ended with positive cumulative gains (+2.6% and +1.2% respectively), suggesting weak timing on exit points. The current sale occurred near the 52-week high (only 2.6% below the $256.81 peak), and LH stock has appreciated 12.9% over the prior 30 days and 3.7% over 90 days, indicating the CEO executed this sale into recent strength. With a P/E of 28.64 and annual revenue growth of 7.0%, the company trades at a premium valuation; the sale reflects portfolio adjustment rather than a signal tied to operational concerns.

LH CEO Schechter sells 6,121 shares at $244.62; holds 88,182 post-transaction amid -18.2% annual revenue decline and 47.00 P/E

Schechter Adam H, President & CEO of LabCorp Holdings, sold 6,121 shares on 2025-02-11 at $244.62, reducing his stake by 6.5% to 88,182 shares and generating $1,497,319.02 in proceeds. The sale occurs as the stock trades near its 52-week high ($251.54) with recent strength: 30-day return of +4.4% and 90-day return of +4.1%. However, the company's fundamentals show material deterioration, with annual revenue declining 18.2% year-over-year to $3,282,000,000.00 and a stretched valuation at P/E of 47.00, suggesting the elevated price may reflect investor optimism disconnected from operational trends. The insider's own prior sales at LabCorp (Nov 2024) did not precede a material decline, and his cross-ticker track record shows a 0.00% well-timed rate on prior sells, indicating no consistent pattern of exiting ahead of downturns. The combination of deteriorating revenue growth, compressed earnings multiple, and a CEO sale near multi-month highs merits observation, though the single-transaction scale and modest 6.5% reduction in holdings limit the urgency signal.

LabCorp CEO Adam H. Schechter sold 6,189 shares at $243.47; holds 87,441 shares post-transaction

LabCorp President & CEO Schechter sold 6,189 shares worth $1,506,835.83 at $243.47 on 2024-11-11, reducing his position by 6.6% from 93,630 to 87,441 shares. The sale occurred at a price near the 52-week high of $246.22, though the stock has rallied +13.5% over the prior 30 days and +9.6% over 90 days. Despite these gains, the company's annual revenue has declined -18.2% year-over-year, and the stock trades at a P/E of 47.26, suggesting market expectations are pricing in future recovery. The transaction represents a modest reduction in an executive's holdings while the stock is near elevated levels—a pattern that warrants monitoring given the disconnect between recent price appreciation and deteriorating year-over-year revenue trends.